Silexion Therapeutics LTD (SLXN) Analysis

Stock Overview

$1.33

+$0.12 (+0.00%)

Volume: 0

Sector: N/A

Industry: N/A

Price Chart

Technical Indicators

Moving Averages

50-Day MA: N/A

200-Day MA: N/A

Relative Strength Index (RSI)

RSI (14): N/A

Neutral

Support & Resistance

Support: $N/A

Resistance: $N/A

52-Week Range

High: $N/A

Low: $N/A

Fundamental Data

Market Cap

N/A

P/E Ratio

N/A

EPS

$N/A

Beta

N/A

Analysis

Note: The analysis provided below is generated for informational purposes only and should not be considered as financial advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.

1. Silexion Therapeutics LTD (SLXN) - Up 9.92%

Analysis: Silexion's substantial gain today extends its impressive weekly rally of nearly 20%, likely driven by the recent positive preclinical data for its pancreatic cancer candidate SIL204. The March 5th announcement of tumor reduction in orthotopic pancreatic cancer models represents a significant milestone for this small biotech company. Context: With pancreatic cancer being one of the most lethal and treatment-resistant cancers, successful preclinical results typically generate strong market interest. The company's small market cap (approximately $11.2 million) makes it particularly sensitive to positive developments. Investors appear to be pricing in the potential value of SIL204 as it moves closer to potential clinical trials, though the stock remains speculative given its early-stage pipeline.

Historical Performance

1 Day

N/A

1 Week

N/A

1 Month

N/A

3 Months

N/A

YTD

N/A

Historical Data

View this stock on other dates:

Back to Daily Report